Our differentiated approach combines human genetic data, deep biological and clinical expertise, and rigorous program selection. We focus on targets with well-established human validation and clear mechanistic rationales to develop first- or best-in-class molecules that deliver transformative benefits in the evolving obesity treatment landscape.
Alveus’ lead program ALV-100 – a GIPR antagonist/GLP-1R agonist fusion protein – is a novel approach validated by human genetics showing that GIPR loss-of-function variants are associated with lower BMI and improved cardiometabolic traits.
ALV-100 is designed to harness the synergistic effects of these mechanisms to deliver sustainable weight loss resulting in a reduced treatment burden for patients.
Importantly, this durable dual approach aims to provide differentiated efficacy beyond current options by addressing counterregulatory metabolic mechanisms that drive weight regain and by improving long-term outcomes. We anticipate entering Phase 3 trials in 2027.
Amylin agonism is a clinically validated biology for weight loss. Amylin signals through the calcitonin receptor CTR and the amylin receptors AMYR1, AMYR2 and AMYR3. Most amylin analogues in clinical development are dual amylin-calcitonin receptor agonists (DACRAs). As with GLP-1R agonists, gastrointestinal adverse effects reduce the tolerability of DACRAs.
The main beneficial metabolic effects of amylin, including lean mass preservation, are suggested to be driven by AMYR3, while gastrointestinal adverse effects such as nausea and aversion are likely due to CTR activation.
AMYR3 analogue ALV-200 shows significant selectivity over CTR whilst maintaining weight loss efficacy in pre-clinical models. ALV-200 is suitable for once weekly dosing, and is currently in IND-enabling development.